Phase 3 Readout~month
Phase 3 Topline: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination Wit
- Company
- Kura Oncology, Inc. (KURA)
- Drug
- either
- Indication
- Acute Myeloid Leukemia (AML)
Other upcoming events for KURA
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.